Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.
FDA Rejects Replimune’s Blood Cancer Drug, Stock Sinks
Where Today's News Shapes Tomorrow
November 14, 2025
Headlines
